HC Wainwright Maintains Buy Rating on LENZ Therapeutics, Cuts Target to $16
HC Wainwright cut its price target on LENZ Therapeutics to $16 per share from $38, while maintaining its Buy rating.
HC Wainwright cut its price target on LENZ Therapeutics to $16 per share from $38, while maintaining its Buy rating.